Fastly, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Fastly, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $356.20M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $295.94M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $266.33M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $209.78M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $187.33M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $170.87M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $112.14M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $79.06M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $56.23M | Mar 4, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($121.68M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($158.06M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($133.09M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($190.77M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($222.70M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($95.93M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($51.55M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($30.94M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($32.45M) | Mar 4, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($119.00M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($167.92M) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | ($198.03M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($246.20M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($219.02M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($107.21M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($46.55M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($29.14M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($31.03M) | Mar 4, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $162.66M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $137.98M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $152.19M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $155.31M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $126.86M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $74.81M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $46.49M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $34.62M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $28.99M | Mar 4, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.44M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $16.41M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $362.0K | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | ($69.63M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($38.48M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($19.92M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($31.30M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($16.99M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | ($25.86M) | Mar 4, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.69M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $10.33M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $10.98M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $19.98M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $34.82M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $29.57M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $14.61M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $16.70M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $12.10M | Mar 4, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.50B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.45B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.53B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.90B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $2.16B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $1.22B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $320.97M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $162.75M | Mar 4, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $569.90M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $486.11M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $545.70M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $940.96M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.15B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $158.09M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $63.32M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $75.10M | Mar 4, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $929.58M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $965.25M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $979.49M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | $955.16M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | $1.01B | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $1.06B | Feb 22, 2024 |
| FY2022 | Dec 31, 2019 | $257.65M | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | ($131.93M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | ($107.01M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | ($78.25M) | Mar 4, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $670.36M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $670.36M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $670.36M | Feb 26, 2025 |
| FY2024 | Dec 31, 2022 | $670.19M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $636.81M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $635.59M | Feb 27, 2023 |
| FY2022 | Oct 1, 2020 | $635.20M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $372.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $360.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $382.0K | Mar 4, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.11B) | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | ($992.81M) | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | ($834.75M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | ($701.66M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($510.89M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($288.19M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($192.01M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($146.19M) | Mar 4, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $180.56M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $286.18M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $107.92M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $143.39M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $166.07M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $62.90M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $16.14M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $36.96M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $31.31M | Mar 4, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $933.21M | Mar 1, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 142.09M | Feb 26, 2025 |
| FY2024 | Dec 31, 2023 | 132.99M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 124.34M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 118.81M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 113.62M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 94.82M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 25.03M | Mar 4, 2020 |